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Summary.-Between 1973 and 1977,247 patients with malignant teratoma have been
treated in two units in London. Seventeen have developed brain metastases, an
overall incidence of 6 2%.
The median survival from diagnosis of cerebral metastases is 6 weeks and all
patients except one have died. The survivor is disease-free 12 months after com-
pleting treatment, which included extensive use of chemotherapy, surgery and
radiotherapy.
Serum gonadotrophin (HCG) and a-foetoprotein (AFP) estimations have been per-
formed in 264 patients as a means of monitoring the effects of therapy. In 42 patients
(37 ofwhom had Stage IV disease) the peak HCG level was >104 iu/l, and the incidence
ofbrain metastases in this group was26%, significantly higher than in the group with
HCG levels below 104 iu/l, for which the incidence of cerebral deposits was 1.8%
(P<0-001). No significant correlation was seen between peak AFP levels and the
incidence of brain metastasis.
With the aim of improving results by earlier diagnosis, cerebrospinal fluid (CSF)
specimens have been examined for HCG and AFP levels in56 subjects, 9 of whom had
brain metastases. A serum: CSF HCG ratio <40 is an accurate indication of the
presence of brain metastases, and may have considerable predictive value. However,
false-negative serum: CSF HCG ratios (>40) frequently occur in patients with
proven brain deposits. Estimation of AFP in spinal fluid has not contributed to the
early diagnosis of brain metastases in malignant teratoma.
IN recent years, the prognosis for
patients with malignant teratoma has
been considerably improved by advances
in chemotherapy as well as in combined-
modality treatment (Williams, 1977). Pro-
longed survival is now recorded, even for
cases with extensive metastases on presen-
tation. However, several adverse factors,
including bulky abdominal disease and
high levels of gonadotrophin (HCG) are
recognized (Quivey et al., 1977). the
development of overt brain metastases is
also generally accepted as a sign of bad
prognosis as they usually occur in the
context of advanced and drug-resistant
tumours.
A recent American series of 240 patients
with testicular teratoma (Vugrin et al.,
15
1978) showed that the subgroup ofpatients
with trophoblastic tumours had a much
higher predilection for developing brain
deposits than other groups, reflecting their
particularly aggressive nature. We have
analysed information on the incidence
of brain metastases in 274 patients with
malignant teratoma treated consecutively
in two referral centres in London between
1973 and 1977, using serum HCG measure-
ments as an index of trophoblastic dif-
ferentiation.
Present chemotherapy has the potential
to control and possibly eradicate these
tumours, but the need to detect CNS
involvement at an early stage may be
crucial. We have therefore examined the
possibility of using spinal-fluid HCC4218 S. B. KAYE, K. D. BAGSHAWE, T. J. McELWAIN AND M. J. PECKHAM
estimation as a tumour marker. Besides
HCG, another index substance detected
in the serum, which has proved useful in
the diagnosis and management in malig-
nant teratoma, is ca-foetoprotein (AFP;
Kohn et al., 1976) and we have also ana-
lysed data on spinal-fluid AFP levels, to
evaluate its possible role as a tumour mar-
ker of brain metastases.
One problem inherent in the use of
tumour markers for localization oftesticu-
lar tumours is the heterogeneous nature
of the metastases which may arise. Differ-
entiation towards trophoblastic or yolk-
sac elements may vary in different sites
in the same individual, and the degree
of necrosis is an additional variable.
Where possible, we therefore report data
on the histological appearance ofthe brain
metastases in this series, particularly in
those cases where spinal-fluid HCG and
AFP levels were measured in live patients.
PATIENTS AND METHODS
Two hundred and seventy-four male
patients have been treated for malignant
teratoma between 1973 and 1977 at the
Royal Marsden Hospital, Sutton and at
Charing Cross Hospital, London. In 266
cases the site of origin of the tumour was
testis, while in 8 cases the diagnosis was made
either on histological examination of extra-
gonadal tissue or on tumour markers.
Using the staging classification of Smithers
et al. (1971), 67 patients were initially treated
as Stage I, 37 as Stage II, 15 as Stage III,
and 155 as Stage IV. Treatment policies have
been continuously developed throughout this
period, but generally chemotherapy has been
the initial treatment for all stages except
Stage I and Stage II with minimal abdominal
disease. Radiotherapy and surgery forresidual
disease in the abdomen or other sites have
also been frequently employed. Tumour
markers, both HCG and AFP, have been
measured serially in the serum of all but 10
cases.
Seventeen patients (6.2%) have developed
symptoms or signs of brain metastases and
details of this group are shown in the Table.
All 17 showed extra-lymphatic spread to
lungs or liver or both, in addition to the
cerebral deposits. In 12 cases there was clear
evidence of progression of metastatic disease
in other sites, chiefly the lungs, before the
cerebral deposits were diagnosed. In the other
5 cases the brain metastases were responsible
for the presenting symptoms of malignant
disease. In the 12 patients who developed
brain metastases after orchidectomy or
biopsy of extra-gonadal tumour, the mean
interval before diagnosis ofthe brain deposits
was 8-7 months (range 5-31). During this
period chemotherapy had been given to 9
patients and abdominal irradiation to 3. The
median survival after diagnosis of cerebral
metastases in the 17 cases was 6 weeks. Only
one patient is currently alive and disease-
free, 12 months after completing treatment.
This was based on a combined-modality
approach, using extensive chemotherapy,
surgery and radiotherapy, and the case is
reported separately (Kaye et al., 1978).
In 59 patients of the series (9 of whom had
brain metastases) CSF was obtained at the
same time as serum for analysis of HCG and
AFP. Several of these patients underwent
repeated lumbar punctures with administra-
tion of intrathecal methotrexate.
Where possible, aliquots of CSF specimens
were taken for estimation of protein concen-
tration and for microscopic examination.
A8say method.-Radioimmunoassay with a
pre-precipitated double-antibody method
was used for measurement of both HCG and
AFP (Kardana & Bagshawe, 1976). All
samples were measured in triplicate. CSF
specimens containing red cells were centri-
fuged before analysis, and equilibration for
protein content was carried out for all CSF
measurements. Between 1973 and 1975,
HCG was measured using antibody to the
intact molecule. From 1975 to 1977 a greater
degree of sensitivity was obtained by using
an assay specific for the beta sub-unit of
HCG: results being expressed in iu/l with
a lower limit of sensitivity of 2 iu/l (0-5 ng/l).
AFP levels are expressed in Hug/l, with
10 jug/l as an arbitrary upper limit of normal.
RESULTS
Serum specimens from 264 patients
were available for HCG and AFP analysis.
Either or both markers were raised in
197 (75%) of patients. Peak serum levels
of HCG in these patients, grouped accord-
ing to clinical stage, are shown in Fig. 1.BRAIN METASTASES IN MALIGNANT TERATOMA
TABLE.- Seventeen patients with brain metastases from malignant teratoma (1973-1977)
Patient
F.K.
S.P.
J.B.
P.M.
M.A.
Histology
of
primary Presenting
tumour symptoms
U Hemiplegia,
headache
U Headache,
coma
I Headache
U Headache,
convulsions
I Hemiparesis
Site of
metastasis
Parietal lobe
Cerebellum,
brain stem
Parietal lobe
Occipital lobe
Parietal lobe
S.S. Not Headache, Parietal lobe
obtaiined hemiplegia
I.S. T Headache, Not localized
diplopia,
papilloedema
R.G. U Blindness Choroid
right eye
*T.T. T Headache, Cerebellum
ataxia,
papilloedema
*M.B. T Hemiparesis Parietal lobe
*I.P. T Hemiparesis, Parietal and
papilloedema occipital lobe
*T.W. T
*F.P. T
Headache,
ptosis
Headaches,
diplopia
*M.P. T Headaches,
hemiparesis
Occipital lobe
Confirmatory
evidence
Isotope brain
scan
Necropsy
Necropsy
Isotope brain
scan
Isotope brain
scan
Clinical oinly
Clinical only
Management
Whole-brain
irradiation
Dexamethasone
Chemotherapy,
dexamethasone
Whole-brain
irradiation
Whole-brain
irradiation
Chemotherapy.
dexamethasone
Dexamethasone
Clinical only Irradiation
Necropsy Whole-brain
irradiation
Isotope brain Chemotherapy
scan (systemic and
intrathecal)
Necropsy Chemotherapy
(systemic and
intrathecal)
Necropsy Dexamethasone
Parietal and Isotope brain
occipital lobes scan
Parietal and
frontal lobes
CT scan, biopsy
U Hemiparesis Frontal lobe Necropsy
*M.P. T Convulsions Parietal lobe CT scan
*N.L. U Convulsions Parietal, frontal, Necropsy
occipital lobes
* CSF samples obtained.
T=malignant teratoma trophoblastic
U= ,, ,, undifferentiated
I= ,, ,, intermediate
CT= computerized tomography
Chemotherapy
(systemic and
intrathecal)
Chemotherapy,
excision, whole-
brain irradiatio
Chemotherapy
(systemic and
intrathecal)
Chemotherapy
(systemic and
intrathecal)
whole-brain
irradiation
Chemotherapy
Survival from
diagnosis
of brain
metastasis
(weeks)
6
1
16
21
39
12
1
37
6
6
4
17
130+
4
38
I
The distribution of patients with brain
metastases according to their peak serum
HCG levels is also shown. The incidence of
cerebral metastases was 26% in those
patients with HCG levels >104iu/1, and
was 18% in those with HCG levels
<104iu/J. Peak serum levels of AFP in
patients with and without brain meta-
stases are shown in Fig. 2. In contrast to
the findings with HCG, it is apparent that
the incidence of brain metastases was
unrelated to peak AFP values.
Data on the CSF concentrations of both
HCG and AFP are presented as the serum:
CSF ratios in each case, since a linear
relationship has been found between CSF
*P.D.
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FiG. 1.-The incidence of brain metastases in
264 patients with malignant teratoma,
classified according to peak serum HCG
levels and clinical stage at presentation.
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FiG. 2.-The incidence of brain metastases
in 264 patients with malignant teratoma,
classified according to peak serum AFP
levels and clinical stage at presentation.
and serum levels ofboth HCG and AFP in
the absence ofbrain metastases (Bagshawe
& Harland, 1976; Kaye & Bagshawe,
1979). Detectable amounts of HCG were
found in the spinal fluid of 25 patients of
the series, 9 of whom proved to have
brain deposits. The ratios obtained are
shown in Fig. 3. In the remaining 34
patients undergoing lumbar punctures
(all without brain metastases) no detect-
able HCG was found in CSF specimens,
though it was present in the serum of 20.
It is apparent that serum: CSF ratios
for HCG below 40 are restricted to patients
with brain metastases, with one exception.
This was a patient with a confirmed
deposit in a lumbar vertebra with posterior
extension into the neural canal, but with
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IFiG. 3.--Serum:CSF,HCGIratiosin25patients
with malignant teratoma, 9 of whom had
brain metastases and 16 of whom had no
evidence of brain deposits. A total of 50
pairs ofsamples were assayed. The 11 ratios
below 40 in cases with CNS metastases were
obtained from a total of 6 individual
patients, in 2 cases before clinical syrnp-
toms developed (see text).
no evidence of an intramedullary lesion
or intracranial tumour. However, ratios
above 40 are also found in patients with
brain metastases, and in 3/9 cases with
confirmed cerebral deposits all the CSF
samples obtained during life gave false-
negative values. A ratio above 40 therefore
cannot be taken as evidence for absence
ofbrain metastasis.
The predictive value of CSF HCG ana-
lysis is indicated by the results from the 4
patients with brain metastases who under-
went lumbar puncture before the develop-
ment of clinical symptoms of brain meta-
stases. In 2, the initial ratio was over 100,
while in the other 2, ratios of9 and 21 were
obtained 26 and 36 weeks before the meta-
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in the series, expressed as the serum: CSF
AFP ratio, are shown in Fig. 4. In the
remaining 15 patients undergoing lumbar
punctures, AFP was undetectable in both
serum and CSF. As with HCG, AFP was
frequently undetectable in CSF when it
was present in serum (in 9 patients) but
unlike HCG there were several occasions
when AFP was detectable in CSF and it
was absent from the serum (in 15 patients).
The data illustrated clearly demonstrate
a lack ofsignificant difference between the
serum: CSF AFP ratios obtained in those
patients with and those without brain
metastases.
In those cases (both with and without
brain metastases) where CSF protein
concentrations were estimated, the values
were within normal limits. In one patient
with brain metastases, microscopic exam-
ination revealed malignant cells in spinal
fluid obtained at the onset of symptoms.
less
than 0.2 1---
CNS NO CNS
METASTASES METASTASES
FiG. 4. Serum: CSFAFPratios in 44patients
with malignant teratoma, 6 of whom had
brain metastases and 38 of whom had no
evidence of brain deposits. Vhen AFP was
present in serum but absent in CSF, the
ratio is expressed as greater than 2. VVhen
AFP was present in CSF but absent in
serum the ratio is expressed as less than
0-2.
stases became manifest clinically. How-
ever, sequential CSF analysis for HCG in
patients undergoing treatment for con-
firmed brain deposits has not proved
helpful in monitoring the course of their
disease. For example, in the patient whose
serum:CSF HCG ratio was 21 several
months before his first convulsion, serial
samples taken over the next 7 months
gave apparently normal ratios ranging
from 71 to 180, despite clinically progres-
sive disease.
The results of AFP estimation of the
serum and CSF specimens of 44 patients
Histological examination
In 8/17 patients with brain metastases,
necropsy was performed, and in 1 other
patient (M.P.) histological examination of
the deposit removed by excision biopsy
was possible.
In 4 of these 9 patients no identifiable
tumour was present in the cerebral lesions;
necrosis and haemorrhage were the pre-
dominant features. The serum: CSF ratios
for HCG in these 4 cases before death were
1155, 1802, 24 and 10.
In only 2 of the remaining 5 patients
with identifiable tumour in the brain
deposits were prior CSF specimens ob-
tained for HCG analysis. The serum: CSF
ratios for HCG in these 2 patients before
death or biopsy were 12 and 4.
DISCUSSION
Our data confirm the experience of
Vugrin et al. (1978) that brain metastases
ofmalignant teratoma occurred in patients
withgeneralizedmetastaticdisease,usually
including the lungs. Their series reported
240 patients with testicular tumours
treatedwith chemotherapy, andtheoverall
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incidence of brain metastases (13.6%)
is higher than in our study. Their results
of treatment of cerebral deposits are
equally disappointing, with a median
survival of 6 weeks to 5 months after
diagnosis of brain metastases, depending
on the histology of the primary tumour.
Trophoblastic tumours, as in our experi-
ence, were particularly aggressive, with
the highest incidence of brain metastases
and the shortest survival after diagnosis.
Tumour markers have been used in the
diagnosis and management of malignant
teratoma for some years, and Braunstein
et al. (1973) emphasized the importance
of monitoring both HCG and AFP. Lange
et al. (1976) have reported that 85% of
patients with testicular teratomas have
an elevation of either or both markers,
using radioimmunoassay for AFP and
for the beta subunit of HCG. The data
reported in our series, showing elevated
markers in 750 of cases, support the view
that measurement of both HCG and AFP
in all patients with testicular tumours is
mandatory.
Bagshawe & Harland (1976) have
demonstrated that CSF HCG estimation
has considerable value in early diagnosis
and in subsequent management of brain
metastases in trophoblastic tumours. This
may play a major role, particularly in
gestational choriocarcinoma, in determin-
ing the success of treatment.
It was hoped that similar principles
might apply in the management of tera-
toma, and our results indicate that to a
limited extent this may be so. For those
patients with predominantly tropho-
blastic tumours, an abnormally low serum:
CSF HCG ratio (less than 40) should raise
the suspicion of brain metastasis, even
when conventional methods of diagnosis
have proved negative. Ratios below 40
are only likely to occur in the absence
of brain metastasis, at a time of a rapid
fall in the serum HCC level, when the
equilibrium state with CSF HCG may not
be reached for several days. In these
circumstances, serial CSF HCG estima-
tions are recommended.
Unfortunately, the accuracy of this
method of diagnosis is limited by the
observation that HCG ratios were appar-
ently normal (>40) in some patients with
brain metastases, before and after the
deposits became evident. Furthermore,
measurement of CSF levels of the other
major tumour marker, AFP, has failed to
show a correlation with the presence of
brain metastases in patients with malig-
nant teratoma. Two explanations are
offered for these findings.
As outlined previously, heterogeneity
in metastases from teratoma may result
in variations in the production of tumour
markers from different sites. Limited data
from necropsies in this series indicate that
necrosis is a particularly common feature
in brain deposits and this may be asso-
ciated with apparently normal serum:
CSF HCG ratios.
Secondly, the persistent elevation of
AFP in CSF fluid when it was absent from
the serum raises doubt about its validity
as a tumour marker for brain metastases.
Normal human CSF in factcontainsseveral
proteins which are absent from serum
(Laterre et al., 1964) and these include an
oc-globulin fraction with the biochemical
properties of glycoprotein similar to those
of AFP. There is therefore a possibility
of cross-reactivity with a normal CSF
constituent in the AFP assay, and results
from a preliminary study on CSF speci-
mens from patients with non-malignant
neurological disease lend support to this
hypothesis (Kaye & Bagshawe, 1979).
CSF protein estimation and cytological
examination generally do not contribute
to the diagnosis of brain metastases.
Analysis for other putative tumour mar-
kers in spinal fluid (Kaye & Bagshawe,
1979) has not been performed in this
series of teratoma patients.
With regard to management, the poor
survival figures indicate failure to control
generalized metastatic disease, particularly
in the lungs, in the majority of patients
with brain metastases from malignant
teratoma. However, the results of treat-
ment for advanced disease continue toBRAIN METASTASES IN MALIGNANT TERATOMA 223
improve, particularly by the use of a
combined-modality approach (Peckham
et al., 1977). Where metastatic disease in
sites other than the brain has responded
to treatment, an aggressive policy for
residual cerebral metastases using chemo-
therapy, surgery and radiotherapy is
justified.
An integral part of this approach would
be early diagnosis of brain deposits in
patients at high risk of developing them
(those with high levels of HCG and pro-
gressive lung metastases). Our data indi-
cate that at present this aim is most
likely to be achieved by regular estimation
of CSF levels of HCG.
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